Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 1.00 |
| ▸ | CDK2 | P24941 | 1/20 | 1.00 |
| ▸ | GSK3B | P49841 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.72 |
| ▸ | HTT | P42858 | 2/20 | 0.72 |
| ▸ | CASP3 | P42574 | 1/20 | 0.72 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.72 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.72 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 6/20 | 0.69 |
| ▸ | RAB9A | P51151 | 6/20 | 0.69 |
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23069040 | 0.94 | AURKA (0.88) | AURKAPIM1CDK2GSK3BSMN1; SMN2 | |
| SCHEMBL1339958 | 0.85 | AURKA (0.74) | AURKAPIM1CDK2GSK3BSMN1; SMN2 | |
| SCHEMBL7261477 | 0.84 | SMN1; SMN2 (0.73) | AURKAPIM1CDK2GSK3BSMN1; SMN2 | |
| SCHEMBL4915214 | 0.84 | SMN1; SMN2 (0.73) | AURKAPIM1CDK2GSK3BSMN1; SMN2 | |
| SCHEMBL27861124 | 0.84 | SMN1; SMN2 (0.73) | AURKAPIM1CDK2GSK3BSMN1; SMN2 | |
| SCHEMBL17207741 | 0.82 | MEN1 (1.00) | AURKAPIM1CDK2GSK3BSMN1; SMN2 | |
| SCHEMBL28796060 | 0.82 | NPC1 (0.71) | AURKAPIM1CDK2GSK3BSMN1; SMN2 | |
| SCHEMBL19501258 | 0.81 | AURKA (0.67) | AURKAPIM1CDK2GSK3BSMN1; SMN2 | |
| SCHEMBL5979445 | 0.81 | AURKA (0.65) | AURKAPIM1CDK2GSK3BSMN1; SMN2 | |
| SCHEMBL4912447 | 0.80 | MAPT (0.72) | AURKAPIM1CDK2GSK3BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3740484-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | AUCENTRA HOLDINGS PTY LTD (AU) | 2020-11-25 | — | — | EP | claimed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | claimed |
| EP-3131877-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | Immunomet Therapeutics Inc. (US) | 2017-02-22 | — | — | EP | claimed |
| CN-106458868-A | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2017-02-22 | — | — | CN | claimed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | claimed |
| CN-111848494-B | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| CN-111848494-A | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| EP-1248615-A4 | THIAZOLE, IMIDAZOLE AND OXAZOLE COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON INC (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20030225146-A1 | Method for treating fibrotic diseases or other indications utilizing thiazole, oxazole and imidazole compounds | SYNVISTA THERAPEUTICS, INC. | 2003-12-04 | — | — | US | disclosed |
| US-6596744-B2 | Administering thiazole compound for therapy of fibrotic diseases | ALTEON, INC. | 2003-07-22 | — | — | US | disclosed |
| US-20020183317-A1 | Method for treating fibrotic diseases or other indications IIC | SYNVISTA THERAPEUTICS, INC. | 2002-12-05 | — | — | US | disclosed |
| EP-1248615-A1 | THIAZOLE, IMIDAZOLE AND OXAZOLE COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | Alteon, Inc. (US) | 2002-10-16 | — | — | EP | disclosed |
| US-20020119970-A1 | Method for treating glaucoma IIB | SYNVISTA THERAPEUTICS, INC. | 2002-08-29 | — | — | US | disclosed |
| US-20020022622-A1 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | SYNVISTA THERAPEUTICS, INC. | 2002-02-21 | — | — | US | disclosed |
| WO-2001052847-A1 | THIAZOLE, IMIDAZOLE AND OXAZOLE COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022622-A1 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | ABAT, NDUFAB1, HSPE1 | AURKA 2088/4885PIM1 774/4885CDK2 441/4885 |
| US-20020183317-A1 | Method for treating fibrotic diseases or other indications IIC | MMP1, COL1A1, COL2A1 | AURKA 4874/4885PIM1 4022/4885CDK2 3063/4885 |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | PC, TFAM, PCK2 | AURKA 1224/4885PIM1 470/4885CDK2 866/4885 |
| US-20030225146-A1 | Method for treating fibrotic diseases or other indications utilizing thiazole, oxazole and imidazole compounds | MMP1, COL1A1, FGF1 | AURKA 4236/4885PIM1 1813/4885CDK2 2001/4885 |
| US-20020119970-A1 | Method for treating glaucoma IIB | NDUFB9, NDUFB2, NDUFB7 | AURKA 3355/4885PIM1 4418/4885CDK2 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.